In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Shaping The Medical Industry, November 2014

You may also be interested in...



Long Road For Daiichi Sankyo’s Quizartinib Gets Longer As FDA Extends Review Time

The drug could nevertheless find itself in a competitive position if approved for frontline FLT3-ITD acute myeloid leukemia, especially as competitor Astellas’s Xospata has repeatedly stumbled.

Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories

Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.

German HTA Queries Polivy Benefits Amid Lack Of Evidence

Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel